Overview

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Status:
Terminated

Trial end date:
2014-11-06

Target enrollment:

Participant gender:

Summary

This study consists of a Phase 1b portion aimed to determine the maximum tolerated dose and the safety profile of PF-03084014 in combination with gemcitabine and nab-paclitaxel followed by a Phase 2 portion to evaluate the efficacy of the triple combination in terms of overall survival in patients with metastatic pancreatic ductal adenocarcinoma not previously treated with anticancer therapies.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Collaborators:

Academic GI Cancer Consortium
Academic GI Cancer Consortium (AGICC)

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel